吉西他滨联合奥沙利铂、替加氟治疗原发性肝癌/胰腺癌疗效观察

Clinical Observation of the Effects of Gemcitabine Combined with Oxaliplatin and Tegafur to Treat Primary Liver Carcinoma/Pancreatic Cancer

目的：观察吉西他滨联合奥沙利铂、替加氟治疗原发性肝癌/胰腺癌的临床疗效。方法：采用吉西他滨联合奥沙利铂、替加氟方案对13例原发性肝癌/胰腺癌患者进行全身化疗,并对其疗效及毒副反应等进行观察。结果：13例患者中,有效率（CR＋PR）为30.8%（4/13）,NC为30.8%（4/13）,（CR＋PR＋NC）为61.6%（8/13）。9个月生存率为61.6%;13例患者中,在前2个周期的化疗后13例患者的CA199、AFP均有不同程度的降低。13例患者均出现血液学毒性,白细胞下降最为明显,表现为Ⅲ~Ⅳ度骨髓抑制。结论：吉西他滨联合奥沙利铂,替加氟治疗原发性肝癌/胰腺癌安全有效。

Objective： To observe the effects of gemcitabine combined with oxahplatin and tegafur to treat primary liver carcinoma/pancreatic cancer. Methods： 13 patients with primary liver carcinoma / pancreatic cancer were given chemotherapy of gemcitabine as priority combined with oxaliplatin and tegafur. The curative effect and toxic / side reactions were observed. Results： The efficiency rate （CR ＋ PR） was 30.8% （4/13） among the 13 patients, NC rate was 30.8% （4/13）, and the rate of （ CR ＋ PR ＋ NC） was 61.6% （8/13）. The 9-month-survival rate was 61.6%. CA199 and AFP level reduced to a certain extent after the first 2 circles of chemotherapy. All 13 patients had haematological toxicity, and teucopenia was the most obvious symptom with Ⅲ-Ⅳ marrow depression. Conclusion： It is safe and effective to treat primary liver carcinoma / pancreatic cancer with gemcitabine combined with oxaliplatin and tegafur.